Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West japan thoracic oncology group study 0301

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 1075-1080

  Kobayashi, Masashi ^a   Matsui, Kaoru ^a   Iwamoto, Yasuo ^b   Ebi, Noriyuki ^c   Oizumi, Satoshi ^d   Takeda, Koji ^e   Sawa, Toshiyuki ^f   Shibata, Kazuhiko ^g   Saka, Hideo ^h   Imamura, Fumio ⁱ   Seki, Nobuhiko ^j   Saito, Hiroshi ^k   Goto, Isao ^l   Nakagawa, Kazuhiko ^m  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f Gifu Municipal Hospital   (Japan)

^g Koseiren Takaoka Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l OSAKA MEDICAL COLLEGE   (Japan)

^m KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Amrubicin; Sequential chemotherapy; Small cell lung cancer; Triplet chemotherapy

Indexed keywords

AMRUBICIN; CISPLATIN; IRINOTECAN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; BRAIN NEOPLASMS; CANCER STAGING; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SECONDARY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954426507     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181dd1591     Document Type: Article

References (20)

1. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355-367. (Pubitemid 351471707)
2. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
3. Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89:1229-1238. (Pubitemid 29008005)
4. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258. (Pubitemid 46774694)
5. Vasey PA, Kaye SB. Combined inhibition of topoisomerases I and II\is this a worthwhile/feasible strategy? Br J Cancer 1997;76:1395-1397.
6. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334. (Pubitemid 28481629)
7. Kudoh S, Nakamura S, Nakano T, et al. Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. Lung Cancer 2005;49: 263-269. (Pubitemid 40966756)
8. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169. (Pubitemid 16140378)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
10. Common Terminology Criteria for Adverse Events, Version 3.0. August 9 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed October 5 2009.
11. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
13. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
14. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.
15. Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? J Thorac Oncol 2007;2:160-165.
16. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453. (Pubitemid 46623179)
17. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
18. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593\a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122. (Pubitemid 32366966)
19. Bozcuk H, Artac M, Ozdogan M, et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer? A metaanalysis of the published controlled trials. Cancer 2005;104: 2650-2657. (Pubitemid 41798275)
20. Kaneda H, Kurata T, Tamura K, et al. A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. Antican-cer Res 2006;26:2479-2485. (Pubitemid 43980221)